Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dementia
Biotech
Lilly pays QurAlis $45M for preclinical ALS, dementia prospect
The deal gives Lilly global rights to QRL-204, a splice-switching antisense oligonucleotide designed to restore UNC13A function.
Nick Paul Taylor
Jun 3, 2024 5:00am
Gene inhibition prevents types of brain damage in mice, cells
Apr 8, 2024 7:20am
Eisai backs C2N's Alzheimer's blood tests with up to $15M
Mar 6, 2024 2:54pm
Passage looks to offload lead program, 2 other assets
Dec 20, 2023 1:29pm
Athira’s losing streak continues with ph. 2 failure in dementia
Dec 12, 2023 9:25am
BioXcel to halve head count, narrow R&D as cash runway crumbles
Aug 14, 2023 8:44am